Nasdaq
$6.30▲ 2.77%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $306.1MShares out 48.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
52- 10.7After-hours26.10.08 05:024Ownership#●●●
Artiva Biotherapeutics, Inc.
Fred Aslan, an insider at Artiva Biotherapeutics, filed a Form 4 on October 7, 2026, reporting a change in beneficial ownership of securities as of October 6, 2026. This filing serves as a routine disclosure of executive stock holdings and does not contain specific transaction volume or price data.…more
$6.30+2.77%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:21144Ownership
Artiva Biotherapeutics, Inc.
Aslan Fred, an insider at Artiva Biotherapeutics, Inc., has filed a Form 144 to report a proposed sale of company securities. This filing serves as a formal notification of the insider's intent to dispose of shares.…more
$6.30+2.77%vs prev closeView filingShare - 10.6After-hours26.10.07 05:024Ownership
Artiva Biotherapeutics, Inc.
Insider Christopher Horan of Artiva Biotherapeutics, Inc. filed a Form 4 report on October 6, 2026, disclosing changes in beneficial ownership of securities effective October 5, 2026.…more
$6.30+2.77%vs prev closeView filingShare
51 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Pre-market26.10.02 22:05#●●●#●●●
Artiva Biotherapeutics to Present AlloNK Clinical Data at ACR Convergence 2026…more
Artiva Biotherapeutics will present updated Phase 2a clinical data for its NK cell therapy, AlloNK, at the upcoming ACR Convergence 2026. The presentations will highlight efficacy and safety in patients with refractory rheumatoid arthritis, supporting the company's progress toward a registrational Phase 3 trial.…more
$6.30+2.77%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Pre-market26.10.01 20:30
●●●●●●●● ●●●●● ●●●●●●
Artiva Biotherapeutics reported positive clinical data from its Phase 2a trial of AlloNK, showing symptom improvement and a favorable safety profile in Sjögren disease patients. These results remain preliminary, and the company continues to evaluate the therapy's efficacy in ongoing studies.…more
$6.30+2.77%vs prev close - 9.23Pre-market26.09.23 20:30
●●●●●●●● ●●●●● ●●●●●●
Artiva Biotherapeutics will present updated clinical data for its AlloNK therapy in patients with Sjögren’s disease at an upcoming international symposium. This presentation serves as a progress update on the company's ongoing clinical development efforts.…more
$6.30+2.77%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report